Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections.

"CONFLICT OF INTEREST DAT has received consulting fees from AbbVie Inc., GSK, and Spero. GJM has received consulting fees from AbbVie Inc. and funding for clinical research from Cempra, Contrafect, and Nabriva. WRM, FAL, RER, and MTS received consulting fees from AbbVie Inc. KK and PG are employees of AbbVie Inc. and may have AbbVie stock. RC was an employee of ICON plc, the CRO supporting study conduct."

"This trial was sponsored by Allergan plc (Dublin, Ireland; prior to its acquisition by AbbVie)."

"Conclusions: Implementation of an ED SSTI clinical pathway for patient selection and follow‐up that included use of a single‐dose, long‐acting IV antibiotic was associated with a significant reduction in hospitalization rate for stable patients with moderately severe infections.: Registration: NCT02961764."